Innovation Pharmaceuticals Inc (IPIX)

[scottsmith]

Why on earth would you claim galera doean’t prevent SOM? Did you forget to read the below passages?

Secondary Endpoints Consistent with Primary Endpoint

GC4419 reduced the incidence of SOM through completion of radiotherapy by 34 percent (p=0.009)
GC4419 also achieved a 36 percent reduction in the overall incidence of SOM through 60 Gy of radiation (p=0.010)
GC4419 reduced the incidence of debilitating Grade 4 oral mucositis (OM) by 47 percent (p=0.045)